tbuckley/cabot-search huggingface dataset:
The Association of Sleep Duration and Quality with CKD Progression
Authors: Ana C. Ricardo, Kristen Knutson, Jinsong Chen, Lawrence J. Appel, Lydia Bazzano, Eunice Carmona-Powell, Janet Cohan, Manjula Kurella Tamura, Susan Steigerwalt, John Daryl Thornton, Matthew Weir, Nicolas F. Turek, Mahboob Rahman, Eve Van Cauter, James P. Lash
Journal: Journal of the American Society of Nephrology (2017)

Evidence suggests that sleep disorders are common in individuals with CKD, but the influence of sleep duration and quality on CKD progression is unknown. We examined the association of habitual sleep duration and quality with CKD progression in 431 Chronic Renal Insufficiency Cohort (CRIC) Study participants, of whom 48% were women and 50% had diabetes (mean age of 60 years old, mean eGFR =38 ml/min per 1.73 m 2 , and median urine protein-to-creatinine ratio [UPCR] =0.20 g/g). We assessed sleep duration and quality by 5–7 days of wrist actigraphy and self-report. Primary outcomes were incident ESRD, eGFR slope, log-transformed UPCR slope, and all-cause death. Participants slept an average of 6.5 hours per night; mean sleep fragmentation was 21%. Over a median follow-up of 5 years, we observed 70 ESRD events and 48 deaths. In adjusted analyses, greater sleep fragmentation associated with increased ESRD risk (hazard ratio, 1.04; 95% confidence interval, 1.01 to 1.07 per 1% increase in fragmentation). In adjusted mixed effects regression models, shorter sleep duration (per hour less) and greater sleep fragmentation (per 1% more) each associated with greater eGFR decline (−1.12 and −0.18 ml/min per 1.73 m 2 per year, respectively; P =0.02 and P &lt;0.01, respectively) and greater log UPCR slope (0.06/yr and 0.01/yr, respectively; P =0.02 and P &lt;0.001, respectively). Self-reported daytime sleepiness associated with increased risk for all-cause death (hazard ratio, 1.11; 95% confidence interval, 1.02 to 1.20 per one-point increase in the Epworth Sleepiness Scale score). These findings suggest that short and poor-quality sleep are unrecognized risk factors for CKD progression.
Novel<i>CLDN1</i>mutation in ichthyosis-hypotrichosis-sclerosing cholangitis syndrome without signs of liver disease
Authors: I.F. Nagtzaam, V.P.M. Peeters, M. Vreeburg, A. Wagner, P.M. Steijlen, M. van Geel, M.A.M. van Steensel
Journal: British Journal of Dermatology (2017)

Ichthyosis-hypotrichosis-sclerosing-cholangitis (IHSC is a rare autosomal recessive syndrome of ichthyosis, scalp hypotrichosis, and sclerosing cholangitis (MIM 607626).[1, 2] Oligodontia, hypodontia and dysplastic enamel have been described as well, as have intracytoplasmic vacuoles in eosinophils, mild psychomotor delay and bilateral anterior uveal synechiae.[2] IHSC is caused by homozygous mutations in the CLDN1 gene which codes for claudin-1, a key component of tight junctions in association with Occludin and junctional adhesion molecules.[2]

This article is protected by copyright. All rights reserved.
SAT0680 The impact of disease activity during pregnancy in women with sle on the birth weight of the child
Authors: ACG Skorpen, S Lydersen, I-M Gilboe, KÅ Salvesen, M Wallenius
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Mean birthweight is lower in children of SLE-mothers than in references. Active disease in pregnancy is considered one of the risk factors. <h3>Objectives</h3> The aim of this study was to explore the association of disease activity in women with SLE in pregnancy and the birth weight of the child expressed as mean birth weight and mean z-score for birth weight. <h3>Methods</h3> We linked data from RevNatus with data from the Medical Birth Registry of Norway (MBRN). RevNatus is a Norwegian nationwide prospective observational register including women with an inflammatory rheumatic disease when planning pregnancy or after conception. The register is administered by the National advisory unit on pregnancy and rheumatic diseases. Women 18 years or older are recruited and followed-up in each trimester of pregnancy and at 6 weeks, 6 months and 12 months after birth. MBRN is a national birth registry. The population constituted all singleton live births recorded in MBRN in the period 2006 – 2014. The births in women diagnosed with SLE in MBRN and included in RevNatus formed the patient group (n=180). The references were all other births (n=498849). Mean birth weight in the patient group was compared to mean birth weight in the general obstetric population. We calculated z-score for birth weight adjusted for gestational age and sex. The target population was then split in two groups according to disease activity assessed in the 2nd trimester, and compared to references. One-way ANOVA was performed to compare SLE-women without active disease, SLE-women with active disease and references from the general obstetric population. <h3>Results</h3> The mean birth weight and mean z-score were both significantly lower in women with SLE compared to references. When comparing three groups, a significantly lower mean birth weight and mean z-score remained between women without active disease and references and women with active disease and references. There were no significant differences between the two disease groups. <h3>Conclusions</h3> Mean birth weight and Z-score was significantly lower in women with SLE compared to the general obstetric population. There were no significant differences in diseased women with active as opposed to quiescent disease. <h3>Disclosure of Interest</h3> None declared
Response to: ‘Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms’ by Reginster <i>et al</i>
Authors: Jos Runhaar, Rianne M Rozendaal, Marienke van Middelkoop, Hans J W Bijlsma, Michael Doherty, Krysia S Dziedzic, L Stefan Lohmander, Timothy McAlindon, Weiya Zhang, Sita Bierma Zeinstra
Journal: Annals of the Rheumatic Diseases (2017)

We appreciate the interest that Reginster and colleagues1 showed in our publication on subgroup effects of oral glucosamine for osteoarthritis (OA).2 We are pleased that the eLetter authors do not put forward any critique of our publication that requires our justification or clarification.

As highlighted by the authors,1 the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned. Nevertheless, due to the heterogeneous nature of the disease, whether certain subgroups of patients with OA could benefit from glucosamine has not been excluded. Since available randomised controlled trials are usually not …
THU0761-HPR Biological therapy survival: multi-centric analysis in real clinical practice conditions
Authors: D García Ybáñez, JJ Alegre-Sancho, A Martínez-Cristόbal, JA Castellano Cuesta, M Fernández Matilla, N Fernández-Llanio Comella, I Ríos-Martin, AM Martinez-Arroyo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Biological treatment (BT) has changed the evolution of rheumatic diseases. A way to evaluate the effectiveness of BTs is considering therapeutic survival as an effectiveness subrogate marker <h3>Objectives</h3> To describe BT use; To evaluate BT survival in indications according to product label, in clinical practice, in 3 Spanish hospitals <h3>Methods</h3> Observational retrospective study, based on clinical history (CH) revisions of patients with Rheumatoid arthritis (RA), Psoriasic Arthritis (PA), and Espondiloarthiritis (EA) treated with BT. CH standardization was performed by data collected since 2013 by rheumatologists thought MEDiadd® RHEUMA tool. Variables: age, gender, indication (RA, PA, EA) TB: Etanercept (ETN), adalimumab (ADA), certolizumab (CRT), golimumab (GOLI), infliximab (IFX), abatacept (ABA), tocilizumab (TCZ), rituximab (RTX). Start and end date from 2002 to 2016 Exclusion criteria: Patients and/or treatment lines with incomplete data (lack data or n&lt;15) were also excluded. Descriptive statistics and Kaplan-Meier survival analysis were performed with r-project.com <h3>Results</h3> From initial 1155 patients, 76 were excluded because of incomplete data. Almost half of the patients (42.35%) were diagnosed with RA, 30.03% have EA and 18.07% PA. 10% were excluded because of other indications. 79.46% of patients with RA are women, as 36.36% of EA and 50.96% of PA; Most of the patients are over 55y. In all indications, the range of 36–54y is the one that present a higher percentage of patients. For the Kaplan-Meier survival analysis, the complete set of BT that each patient had received was analyze independently, considering 1206 cases. Table 1 shows average time and percentage survival at 1st year After 1 year, ETN showed the higher rates of survival in RA (98.5%); IFX (100%), and ETN (99%) in PA; and GOLI (100%) followed by ETN (95.8%) in EA. Those BT were used to compare survival curves, finding differences in all cases (α=0.05) except in IFXvsETN in RA; ETNvsIFX in PA; and IFXvs GOLI in EA. Analysis after 5 years showed that the higher survival rates were for IFX in RA (94.4%) and PA (94.7%) and for ETN in EA (89.4%) <h3>Conclusions</h3> BTs with highest survival rates are ETN and IFX for RA and Aps; In EA, GOLI presents a higher rate at 1-year, but at 5-year is overcome by ETN Standardized information is crucial to assess the global impact of BT. CH analysis reveals clinical practices which describe the effectiveness of treatments in the world, which can help in the decision-making process <h3>Acknowledgements</h3> By their collaboration: Dr Casado; Dr Valls; Dr Martinez; Dr Aguilar; Dr Vergara; Dr Begazo <h3>Disclosure of Interest</h3> None declared
Steroids Abrogate BiTE® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells
Authors: Christina Krupka, Bettina Lindl, Thomas Köhnke, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, Torben Altmann, Peter Kufer, Roman Kischel, Wolfgang Hiddemann, Marion Subklewe
Journal: Blood (2016)
Paris Agreement’s ambition to limit global warming to 1.5°C still possible, analysis shows
Authors: Ingrid Torjesen
Journal: BMJ (2017)

The ambitious aim, set by the Paris Agreement in 2015, of limiting global warming to less than 1.5°C is still feasible, an analysis shows.1

The agreement aims to hold the increase in global average temperature to below 2°C above pre-industrial levels, and countries signing up to it agreed to pursue efforts to limit the increase to 1.5°C.

The 1.5°C aspiration was seen as unachievable because analysts predicted that carbon emissions would need to fall to zero within seven years. However, the new analysis, based on the latest …
TRPA1 activation in a human sensory neuronal model: relevance to cough hypersensitivity?
Authors: Rebecca Clarke, Kevin Monaghan, Imad About, Caoimhin S. Griffin, Gerard P. Sergeant, Ikhlas El Karim, J. Graham McGeown, S. Louise Cosby, Timothy M. Curtis, Lorcan P. McGarvey, Fionnuala T. Lundy
Journal: European Respiratory Journal (2017)

The cough reflex becomes hyperresponsive in acute and chronic respiratory diseases, but understanding the underlying mechanism is hampered by difficulty accessing human tissue containing both nerve endings and neuronal cell bodies. We refined an adult stem cell sensory neuronal model to overcome the limited availability of human neurones and applied the model to study transient receptor potential ankyrin 1 (TRPA1) channel expression and activation. Human dental pulp stem cells (hDPSCs) were differentiated towards a neuronal phenotype, termed peripheral neuronal equivalents (PNEs). Using molecular and immunohistochemical techniques, together with Ca 2+ microfluorimetry and whole cell patch clamping, we investigated roles for nerve growth factor (NGF) and the viral mimic poly I:C in TRPA1 activation. PNEs exhibited morphological, molecular and functional characteristics of sensory neurons and expressed functional TRPA1 channels. PNE treatment with NGF for 20 min generated significantly larger inward and outward currents compared to untreated PNEs in response to the TRPA1 agonist cinnamaldehyde (p&lt;0.05). PNE treatment with poly I:C caused similar transient heightened responses to TRPA1 activation compared to untreated cells. Using the PNE neuronal model we observed both NGF and poly I:C mediated sensory neuronal hyperresponsiveness, representing potential neuro-inflammatory mechanisms associated with heightened nociceptive responses recognised in cough hypersensitivity syndrome.
SP0151 Switching off unwanted immune responses: the mechanism of antigen-specific immunotherapy with t cell epitopes
Authors: DC Wraith
Journal: Annals of the Rheumatic Diseases (2017)

Control of autoimmune and allergic conditions can be reinforced by tolerance induction with peptide epitopes; this presentation will focus on the mechanisms involved. Peptides must mimic naturally processed epitopes. Peptide induced peripheral tolerance is characterised by the generation of anergic, IL-10 secreting CD4<sup>+</sup> T-cells with regulatory function. CD4<sup>+</sup> T-cells become anergic following their first encounter with peptide. The loss of proliferative capacity correlates with a cytokine switch from a pro-inflammatory to a phenotype characterised by secretion of the anti-inflammatory cytokine IL-10. IL-10 Treg/Tr1 cells suppress dendritic cell maturation, prevent Th cell differentiation and create a negative feedback loop for Th driven immune pathology. Tolerance induction involves upregulation of transcription factors controlling IL-10 and inhibitory receptors limiting T cell signalling. Results from clinical trials of peptide immunotherapy will be discussed. <h3>Disclosure of Interest</h3> None declared
FRI0287 Incidence of lupus nephritis and 18-month follow up in colombian patients with systemic lupus erythematosus
Authors: MA Alzate, D Hernandez-Parra, JC Salazar-Uribe, P Ortiz-Salazar, R Pineda
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Lupus nephritis (LN) is one of the major indicators of poor prognosis in patients with systemic lupus erythematosus (SLE). Multiple studies with Latin-American SLE population have shown a higher prevalence of LN, higher severity, and less favorable outcomes (1). <h3>Objectives</h3> To determine the incidence of lupus nephritis and end-stage renal failure, as well as evaluate progression of renal function and proteinuria during an 18-month follow up in colombian patients with SLE. <h3>Methods</h3> A retrospective cohort study was conducted in 1448 patients with SLE, 41 of which were diagnosed with LN between August/2014 and July/2015. Follow up was made for 18 months, analyzing glomerular filtration rate (GFR) and proteinuria, induction and manteinance therapy, renal relapses, hospitalizations and mortality. Univariate analysis was done to describe sociodemographic and clinical variables. Longitudinal data analysis was performed using linear mixed models with random intercepts. In all cases, a p value &lt;0.05 was considered statistically significant. <h3>Results</h3> Clinical characteristics of patients with LN are shown in table 1. Eighty-five percent of LNs where biopsy-proven. Incidence of LN was 2,83 cases/100 SLE patients/year. The incidence of end-stage renal failure was 7,31 cases/100 LN patients. During the 18-month follow up, 34% of patients had hospitalizations related to SLE activity or complications, 7,3% renal relapse, 2,4% rebiopsy, and no mortality cases. Induction therapy was done with cyclophosphamide in 58,5% and with mycophenolate mofetil in 41,4%, with 30% of the patients requiring re-induction therapy, Ten percent of patients required use of rituximab due to refractory response to multiple treatments. In longitudinal linear analyses, age at diagnosis and anti dsDNA was positively associated to GFR variations (Figure 1,A), while anti Sm, hematologic involvement and biopsy classification were associated to proteinuria variations during time of follow-up (Figure 1,B). <h3>Conclusions</h3> In a real life scenario, anual incidence of lupus nephritis was 2,83 cases/100 SLE patients. A high proportion of patients with refractory response to multiple immunomodulatory treatments for LN were identified. <h3>References</h3> Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus. 2015;24(6):536–45. <h3>Disclosure of Interest</h3> None declared
AB0223 Prognostic factors for radiographic damage in patients with seronegative rheumatoid arthritis
Authors: HY Lee, E-J Park, WS Jeong, J Kim
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Long since it have been suggested that seronegative rheumatoid arthritis (RA) represents a clinical entity quite distinct from that of seropositive RA. However, analytical studies dedicated to clinical outcomes regarding radiographic progression and risk factors for that are scarece<sup>1,2</sup>. <h3>Objectives</h3> The aim of this study is to evaluate radiographic outcome and prognostic factors for radiographic damage in patients with seronegative RA. <h3>Methods</h3> RA pateints reportedly seronegative for both rheumatoid factor and anti-cyclic citrullinated peptide antibody who were seen at Jeju National University Hospital in South Korea between August 2003 and December 2016, and followed-up at least 2 years were included. Medical records, laboratory and radiographic data was retrospectively analyzed and multivariate analysis was performed to evaluate prognostic factors for radiographic damage in patients with seronegative RA. <h3>Results</h3> One hundred six patients with seronegative RA were observed and 16 (15.1%) patients demonstrated newly-developed joint damage during follow-up period. Age at diagnosis was 38.9 years and 64 (60.4%) patients were female. Symptom duration at diagnosis was 1.1 years and follow-up duration was 4.4 years. Baseline characteristics including sex, symptom duration, smoking status, number of active joints, acute phase reactant, joint erosion at diagnosis were not significantly different in patients with joint damage compared to those without joint damage. Joint erosion at diagnosis and smoking status were associated with radiographic damage in seronegative RA adjusting age, symptom duration, ESR, CRP values at diagnosis, and follow-up duration, whereas it was not statistically significant (adjusted odds ratio 1.45;p=0.061 and 1.58;p=0.072 respectively). <h3>Conclusions</h3> Our study demonstrated a rate of joint damage in patients with seronegative RA comparable to recent studies. Joint erosion at diagnosis and smoking status showed tendency to correlate with progression of radiographic damage in patients with seronegative RA. A large comparative study dedicated to this issue in seronegative RA is required. <h3>References</h3> Ajeganova, S. &amp; Huizinga, T. W. J. Nat. Rev. Rheumatol. 11, 8–9 (2015). A.G. Pratt, J.D. 652 Isaacs/Best Practice &amp; Research Clinical Rheumatology 28 (2014) 651e659. <h3>Disclosure of Interest</h3> None declared
SP0143 A new day for people with psoriatic arthritis: a heterogeneous disease that can be treated well?
Authors: LC Coates
Journal: Annals of the Rheumatic Diseases (2017)

This talk will summarise recent advances in research around the treatment of psoriatic arthritis (PsA). Firstly there will be an update on research that shows the importance of treating patients promptly when they are diagnosed. Then results from studies of new therapies for both psoriasis and psoriatic arthritis will be shown to highlight the drugs that have recently become available in the clinic or are likely to be become available in the next few years. This will include new biologic disease modifying drugs with different targets including those that target interleukin 17 and interleukin 23 as well as new oral medications that are part of a family called small molecules. The role of these new therapies and how they compare to existing therapies in the clinic will be addressed. Finally there will be a summary on the research of how to use the existing and new therapies in the clinic including the use of the "treat to target" strategy. <h3>Disclosure of Interest</h3> L. Coates Grant/research support from: Abbvie, Janssen, Consultant for: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sun Pharma, UCB
THU0618 The factors affecting workplace and household life in ankylosing spondylitis: a multi-dimensional study
Authors: B Taser, FF Ayhan, P Borman, A Karagöz
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Work disability (WD) is the final stage of work problems and may be prevented by effective treatment and ergonomic interventions in earlier stage of work productivity loss and work instability. Contextual factors, disease related factors and local social security systems may also affect WD. <h3>Objectives</h3> We aimed to determine the predictive factors of work productivity and work stability in Turkish patients with ankylosing spondylitis <h3>Methods</h3> One-hundred patients with ankylosing spondylitis (31 females and 69 males) were included into this study. Demographics, working state, Bath scores of disease activity, functional and radiologic state, quality of life, cardiopulmonary functions (echocardiography, exercise stress test and pulmonary function test) and general work impairments (work productivity impairment and work instability) were recorded. WPAI and AS-WIS were selected as work outcomes. The most predictive factors were analyzed in work productivity and work instability. SPSS 14.0 statistics (descriptives, pearson correlation, and stepwise regressions were used for statistical analyses. <h3>Results</h3> Thirty-two patients (mean age: 42,6±11.7) were unemployed. Unemployed patients showed more female, less educated, low disease activity, and low fitness profile. The percentages of absenteeism (WPAI-1), presenteeism (WPAI-2), regular activity impairment (WPAI-3) and overall work impairment (WPAI-4) were determined as 8, 44, % 47, and % 37, respectively, in employee group. When affecting factors assessed with multiple stepwise linear regression analysed; the only determinant for absenteeism (WPAI-1) was the working day loss due to ilness at last year. Chest mobility, annual income level, AS quality of life (ASQoL), work change and co-morbid diseases were the determinants of presenteeism (WPAI-2), regular activity impairment (WPAI-3) and overall work impairment (WPAI-4). The score of mean work instability (AS-WIS) was 11.5±5.8, and 42.6% of patients had low and 57,4% of patients had moderate-high work instability. Multiple stepwise linear regression analysis showed that most predictive factors for work instability were regular activity impairment (WPAI-3) and AS-QoL. The factors affecting non-work status were older age, female sex and low annual income level in stepwise logistic regression. <h3>Conclusions</h3> The common predictive factor of work productivity and work stability was quality of life. For evaluation of work productivity; socioeconomic factors such as annual income level and frequent work change were determinative as well as clinical datas (chest expansion and comorbid diseases). We suggested both pharmacologic and nonpharmacologic interventions to improve quality of life should be enabled in early period to improve work productivity. <h3>Disclosure of Interest</h3> None declared